Vaccine Program Could Spawn Opportunities For Researchers

A report released last month by the Institute of Medicine (IOM) proposes the creation of a National Vaccine Authority (NVA) to oversee the entire process of vaccine research and development in the United States. The authority will also act as a liaison between the federal government and private industry for vaccine production. The report discusses, among other topics, the role of applied research in the development of new or improved vaccines against such diseases as tetanus and cholera both

Written byRon Kaufman
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The report discusses, among other topics, the role of applied research in the development of new or improved vaccines against such diseases as tetanus and cholera both in the United States and internationally.

Though the report does not directly address expanded vaccine research opportunities under the proposed authority, Violaine Mitchell, the study director at IOM, says investigators may be attracted to a more directed approach.

"In terms of funding streams it might help direct attention to areas of top priority and attract new researchers there," she says. "On the other hand, so much of what science does well is allowing investigator-initiated research to explore new opportunities."

The report, entitled The Children's Vaccine Initiative: Achieving The Vision (Washington, D.C., National Academy Press, 1993), was produced by an 18-person committee whose members represent academia, industry, government, and nonprofit groups. The committee met on a regular basis between February 1992 and February 1993 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies